{
  "url": "https://finance.yahoo.com/news/ose-immunotherapeutics-proposes-governance-evolution-050000347.html",
  "authorsByline": "OSE Immunotherapeutics",
  "articleId": "8756e28fd81943ebb2c13aac894a7a2a",
  "source": {
    "domain": "finance.yahoo.com",
    "location": {
      "country": "us",
      "state": "CA",
      "county": "Santa Clara County",
      "city": "Sunnyvale",
      "coordinates": {
        "lat": 37.3688301,
        "lon": -122.036349
      }
    }
  },
  "imageUrl": "https://s.yimg.com/ny/api/res/1.2/RDvsduQkOGy8Ji3CZlDZSA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD00MDA-/https://media.zenfs.com/en/globenewswire.com/30f72419d0291606fc6eb96fa53d5067",
  "country": "us",
  "language": "en",
  "pubDate": "2025-08-25T05:00:00+00:00",
  "addDate": "2025-08-25T05:13:56.194555+00:00",
  "refreshDate": "2025-08-25T05:13:56.194559+00:00",
  "score": 1.0,
  "title": "OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting",
  "description": "OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General MeetingNew Board Structure Reflects Balanced and Proportionate Shareholder Representation New Governance to Drive Strategic Roadmaps for Tedopi\u00ae and Lusvertikimab Nantes, August 25, 2025, 7:00 a.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces the convening of its Annual General Shareholders\u2019 Meeting, to be held on September 30, 2025, along with a proposed",
  "content": "OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting\n\n\n\nNew Board Structure Reflects Balanced and Proportionate Shareholder Representation \n\nNew Governance to Drive Strategic Roadmaps for Tedopi\u00ae and Lusvertikimab Nantes, August 25, 2025, 7:00 a.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces the convening of its Annual General Shareholders\u2019 Meeting, to be held on September 30, 2025, along with a proposed evolution in its governance. This move reinforces the company\u2019s commitment to balanced and proportionate shareholder representation and strategic alignment. The proposed governance framework is in the context of ongoing discussions with concertist shareholders. It aims to ensure international expertise, while maintaining independence and continuity to support the company\u2019s two key therapeutic areas, and to explore all strategic options in the best interests of patients and all shareholders. The proposed reshaped Board structure would comprise: two seats for current independent Board members; two for new independent directors, two for concertist shareholders (representing 20% of the shareholder equity); one for the CEO; and one for the representative of employee shareholders. As a consequence of this evolution, certain directors would step down or not renew their mandates. This reshaped Board is designed to reflect the diversity of its shareholder base and to prepare OSE for its next strategic opportunities and challenges. Didier Hoch, Chairman of OSE Immunotherapeutics, commented: \u201cOSE is ready for its next chapter. The proposed changes aim to create a smaller, more agile and strategically aligned Board, one that reflects the interests of all shareholders. This evolution reflects our commitment to sound governance and effective oversight, supporting the Company\u2019s strategic and financial objectives. Constructive discussions are still ongoing with concertists, with the shared goal of reaching a balanced understanding.\u201d Alongside governance updates, the Company\u2019s strategy remains focused on unlocking the full potential of Tedopi\u00ae and Lusvertikimab through continued development with strategic partnerships and financings. Strategic options to develop and maximize the value of these two therapeutic platforms are being explored. Management is therefore actively pursuing business development partnerships and targeted non-dilutive and dilutive financing opportunities to ensure both programs are fully resourced and positioned for success, each with its distinct development roadmap.\n\nNicolas Poirier, CEO of OSE Immunotherapeutics added: \u201cWhile governance has required attention, our scientific and strategic path remains unchanged: to unlock and maximize the potential of both Tedopi\u00ae in oncology and Lusvertikimab in inflammation until the next value-inflection points. Recent momentum in the IBD space has further reinforced interest and appetite, validating the value-creation approach with Lusvertikimab. This is the moment to accelerate, not to step back.\u201d Addressing the questions raised by certain shareholders, the company confirms pursuing the strategic pivotal phase 3 of Tedopi\u00ae in lung cancer but not pursuing any immediate large-scale phase 3 study in IBD. Instead, Lusvertikimab will enter a focused, cost-efficient phase 2b study designed to determine optimal dosing, validate the subcutaneous formulation, and explore a predictive biomarker before entering pivotal phases, reflecting important feedback from potential partners. This measured approach ensures scientific rigor, financial discipline and optionality. \u201cOur goal is to protect the value we\u2019ve created with our two key assets and secure the right financial and strategic flexibility to deliver for patients and shareholders. Tedopi\u00ae\u2019s phase 3 is advancing well, and we plan to complete enrolment next year. Precision immunotherapy or smart combinations are set to redefine efficacy standards in chronic inflammation. Lusvertikimab is uniquely positioned to achieve both objectives; it could, for the first time, enable precision medicine to break through today\u2019s efficacy ceiling in IBD. Our focus is to preserve all optionality while maintaining operational agility and clarity in execution,\u201d added Nicolas Poirier. The combined AGM will take place on September 30, 2025, at 10:00 a.m. CET, at the Drawing House Hotel, 21 rue Vercing\u00e9torix, 75014 Paris. The convening notice, including the agenda, proposed resolutions, and participation details, are published today in the Bulletin des Annonces L\u00e9gales Obligatoires (BALO) and will be available on the Company\u2019s website: https://www.ose-immuno.com/assemblees-generales/. For the first time, shareholders will be able to vote electronically via the Votaccess platform, and the AGM will be broadcast live in line with new regulations. Written questions may be submitted in advance, and voting by correspondence and proxy is available. In advance of the AGM, OSE will host a shareholder webinar on September 18, 2025, at 6:00 p.m. CET, to present key updates and engage directly with shareholders. Details below.\n\n OSE Immunotherapeutics is a biotechnology company developing first-in-class products in immuno-oncology (IO) and immuno-inflammation (I&I) to address the unmet needs of today's and tomorrow's patients. We partner with leading academic institutions and biopharmaceutical companies to combine our efforts to develop and bring to market transformative medicines for people suffering from serious diseases. OSE Immunotherapeutics is based in Nantes and Paris and is listed on Euronext. More information on OSE Immunotherapeutics' assets is available on the Company's website: http://www.ose-immuno.com \n\nFollow us on Linkedln. Forward-looking statements\n\nThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics\u2019 management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as \u201cexpect\u201d, \u201canticipate\u201d, \u201cbelieve\u201d, \u201ctarget\u201d, \u201cplan\u201d, or \u201cestimate\u201d, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics\u2019 shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics\u2019 website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.",
  "medium": "Article",
  "links": [
    "https://www.globenewswire.com/Tracker?data=Mhkt4Dxw5j5LSHTXwp6-ydYYsMnbrtKoDEeKIO5J8XN36qjVa0tBsIrLpAX_Hz3zJIGayNylUnOzICGK9HmwUcdCLn9zTYG1p9TrMua3LrZoavH4o_J8258pByv58QePeL_9UuUFv6dOY-X_HbAWQQ==",
    "https://www.globenewswire.com/Tracker?data=OVYCoOW_SA_xNMoG6kPgG4bNcy-KikusOXW6k8jAbXaxRz8beLkJyuOXM9gs2zcu1OF_5eCxr-QkCkEzwpjIBhjaaCDjldgWj3I_92MxYsB42X8RYKel4TweIh92xjube8D7P1Ct7oRbFvXYrv8y4yMV7ToGKkJ0VGfKyVk-qNsocWK1T2ToTl4iwv2jZT5ju-OJgPiNLHor6JpuRAooess7vBlboJgU_-gBroCvuDpKO5LQFF5jmac8uwwrDqGMBSzRv9Us-Xv17_FsR92QTX2OCEqIdt2dhTEB9J8pUPkw4_FOjp8xz_maMTm-pEV1Gv--InrFBYga-_DvWIrd8WP2kj2j6S3l9eWXDXCBplwVRtbSZZ_2Nn0abJVXuLVvHzEaheOzMEDo9ouzav90bQZxnSBgRDQ0uAFLjZlWSMuw7SsFGvwmnxq_r-84-tivSdFV0XjqYUdwurtAknNW_WQriKv5BbPfx7K5SM-IZDldJdZPfzZrtzWBhEcAnMZt56rRYjscOqgMCmZnEJT1_9Et_PP3cYZU9oU1jnmUirFVGq0BvTZpooj6CY66TEqZ-3Vt9uwe3B4ng-ePwQLSBBNs3quQ5g2I3NGfj1kBxQ9qKeJ4qrNmR7GHccn30BEIJLCv5k6SOOUbzP7oQ9QoMglNp-h8KbmzsZjaPWGnHtSVeIs3bx6_QaYPEAD44G3vi8lXXCFuaKIbZ_jSnL8bk-gBwBqbJ3qACaDRJ4KR07QB6ePPiV-S6DMSOknwe4YD4N1zvbqk0_g_Niz2UhkN4DQOk4GrSBIKtsGW5G1gLz4xOEh0mjdhsHvgDHw8CfhdkVZECHZApe4uI7SngkrUJaqBpt3-2M-UxbPabTQlrUJEUq50-E0Exz5718dvpKCQ-WAp5OYGSQWHQvKLWiSbQ7VV5oOWcRr-8bVNHnJ4W5X9aJbrDp4gdiSsrEnj-o9oIVHuRcsw32rbM1B5HljP_gWZhy7OsjT7bSrUdsf5KtwIeWyOcV0JKmNsOjPaPT0kY15ROYZktD3h3hfpTgAKmS5uEsAG1iX6Vtt6YcqQf26Fy_STKBUcWItK99kAQOGaYlqwB_3Kcylq4dQAizpX1gSTHAEjnEO6QYF_absY0ek=",
    "https://www.globenewswire.com/Tracker?data=R7E0LSJiSN-VJ3ohgoXUCJ2q-RwnreXFWiaXZHhzMKNcY3Lh9jdHM2K2HZBOQb0Ggrzq5XQbvHDT0QEeBb4i9GAFBZLb6FFknHo8DTdUgrzuZ5gtpTMP-Xh5CUgp5oS61AXK4hMHRH1li3d1ronVst-yWLg1wwLETuPiRfNcP6s=",
    "https://www.globenewswire.com/Tracker?data=OVYCoOW_SA_xNMoG6kPgG4bNcy-KikusOXW6k8jAbXaxRz8beLkJyuOXM9gs2zcu1OF_5eCxr-QkCkEzwpjIBhjaaCDjldgWj3I_92MxYsB42X8RYKel4TweIh92xjubP5pgovJangcXRQrIRyUtVcQQ6DPFT70UaOTXQcQxD1K9PLjYAtnjZG_mBcKucKQQJm4Gg83H-lecTogQ79JK9mUAo6700ikJOYUosUqR005mJBXJcgijPfaO_Fyzu1_RpBWKpWs7KwWewBaTt7L6CettAFr4XmcGf4pj-V2jyKx07V3H_ue6dubLbwZxz_TRqc7uuOkmWD3bP4K8RVxyEk_TEA5teBBgo8PkSh1156Um5ovIT03ypCo2Qw2LnUUEeu2epnvmVpWzWv2Uwhl2wyNmbsxehXkNHxcUSW54GUySw9sV9igV-OEfplhjYbxI86IWL2moJx-6gOsUaGZQBxYz7f8lGELp-TtI2TTlW0QvETsGHPpfrlrerk6K3T1xEugB_o5vCAKi7oczw8Qt3SGdQpvEKmr5nGsmKrG13OxSzQS-Edm71jndvdA3Z-ZZy2UB3fWrIL8iShdASXHkKBGuqnj3RVhM1Qd7ZB7xGn2riqHBGC2hPTInQFFiUqG0S8_CHbRG0E5BGOWzr9AyAi8h8DYVuDgP-wrtNaVrYs68ccwn_aYjBsmOeqvsqZgJP_pvl-9hKf6Dwmal5XhHkdZneLk5YBqEv_PDfEVyxN0fnYsRerxwY1y9-5UaeenqKMZpHrCtlpnCnLzQ4KuD77A4HaDPL8vqUC3tVncOD-Hu1MNJsvBaUHkNf-imuwPTncvuEOQ4ReiFAAVS_AR5VVbt8oKxaRja9qd9n1bOwVwQy_qWIcSPPXk8k-4FJeQtBQWAndDP-vTB83KnMVHUyB2ZAKtdbPDOGJqzMmVg15KYYvAo46XLH3pCaeiD6re92eJSAHI86BPuSRJaZHJVRAfvFF3bq8Y6RDq0qpJ-pqOFatgyUkTNUX3IvzcOI00CY5IamqzK4AvmBzWLsJjyO3rj6Nd15Yl0B3iNBarrmrbaNxUnb-fSIIhyAfa5tuw1--DcvESBgwLi0-6z-TsMmgB5yfSZJav8meZWO2H_vNo=",
    "https://www.globenewswire.com/Tracker?data=WgSp31CXadUE2xKcu9btKbu8P6LeBaASPiy4za6JMyZVlzVrHVVoPZqX66vGyOmX_v2wcyqynEYrGBdZbnceQ8WyB3bwGpGSFCwuZlQWwD-oq0DYd_uHrEee8JdMkUyBB5e7r53voblAqhBvuiCzzyLvwlanw3rkXsAg5iXLrbw=",
    "https://www.globenewswire.com/Tracker?data=Wb0f8RaeTtq98LHj4vAdollQnj4DA34He-2n3HSPhkMwJWVmi2ffjWB9ZVXuNjmEW1-W8cA6aGbrCy0zN9cek6n11Xxvi-RBu0bAZpsMTSMJUIfAEPsT2v2MNNF-ZyvJHq2A9clTR2uq2cLdb9fff4aBwuhonMj_o2mnqei8CxbiSdi7_PGYG1UQrBs9zCbCLo78MR5xOl0rN5JGtk3HIMbP-06ubP6HXfgTw-o9c9KcPt7ucMj1vncb08ZM0OMK8RWzOBQLkrlOpGkbotpBeWY5nzPxIXgziKQtcDr97IOKED5zaqDLvTfRzZ-FoUvNDvxNqNeuJn075kIAQ-Pi3cn8QWsR18l2fFbOcU3S-HUPowbG05Xroyy8BZh3N6CvLEFsMAlNPCVGmZ3IUMPV5E402whdwzkZfPazzPX4YzwzV-7Nz7xr0n6Urfi_3ili2RgZIFCs3nwV618hgbWe7S73fWOU9IdPPJG7H8yaP35AhNxy2FjPvpfJm5kcSB7LXCLYACpq51M46rXWBmIMnXnWskMpNTqdWZyiafE2Dv-meU0G89ZXt_IcQ7k5zzTWr42ud0aROY8kIwOJqZ370uQYkGhKKwCTmn_G0KYH7DgFZvmA9KkKBJWJwvC8ex1sURRZsY1XHka4VrfITWkSZ8jRXAhIqfyjz2YBCcw7AJK6j6DqHpLmeCeeT6EOKnl7auSrmwVtuylBBn4br7qduQ=="
  ],
  "labels": [],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "OSE Immunotherapeutics",
      "weight": 0.08919077
    },
    {
      "name": "OSE Immunotherapeutics SA",
      "weight": 0.083794735
    },
    {
      "name": "OSE",
      "weight": 0.070690006
    },
    {
      "name": "certain shareholders",
      "weight": 0.069136366
    },
    {
      "name": "concertist shareholders",
      "weight": 0.065996565
    },
    {
      "name": "shareholders",
      "weight": 0.06446844
    },
    {
      "name": "employee shareholders",
      "weight": 0.06357864
    },
    {
      "name": "Strategic Priorities",
      "weight": 0.062593125
    },
    {
      "name": "strategic partnerships",
      "weight": 0.062428996
    },
    {
      "name": "Strategic options",
      "weight": 0.062112108
    }
  ],
  "topics": [],
  "categories": [],
  "taxonomies": [
    {
      "name": "/News/Business News/Company News",
      "score": 0.9853515625
    },
    {
      "name": "/Business & Industrial/Pharmaceuticals & Biotech",
      "score": 0.88671875
    },
    {
      "name": "/News/Business News/Financial Markets News",
      "score": 0.88134765625
    },
    {
      "name": "/Finance/Investing/Stocks & Bonds",
      "score": 0.82177734375
    }
  ],
  "sentiment": {
    "positive": 0.465232,
    "negative": 0.047922596,
    "neutral": 0.48684534
  },
  "summary": "OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) has proposed a governance evolution ahead of its Annual General Shareholders\u2019 Meeting on September 30, 2025. The move aligns with the company\u2019s commitment to balanced and proportionate shareholder representation and strategic alignment. The proposed Board structure would include two seats for current independent Board members, two for new independent directors, one for the CEO, and one for employee shareholders. As a result, certain directors would step down or not renew their mandates. The company's strategy remains unchanged to unlock the potential of Tedopi\u00ae and Lusvertikimab through continued development with strategic partnerships and financings. Management is also exploring business development partnerships and targeted non-dilutive and dilutive financing opportunities for both programs.",
  "shortSummary": "OSE Immunotherapeutics proposes a new board structure to enhance strategic awareness and collaboration, while continuing with drug development and financial flexibility.",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": false,
  "reprintGroupId": "9186f534e0c646998e1ecd9a6b8d5351",
  "places": [],
  "scraped_sources": [
    {
      "url": "https://www.globenewswire.com/Tracker?data=Wb0f8RaeTtq98LHj4vAdollQnj4DA34He-2n3HSPhkMwJWVmi2ffjWB9ZVXuNjmEW1-W8cA6aGbrCy0zN9cek6n11Xxvi-RBu0bAZpsMTSMJUIfAEPsT2v2MNNF-ZyvJHq2A9clTR2uq2cLdb9fff4aBwuhonMj_o2mnqei8CxbiSdi7_PGYG1UQrBs9zCbCLo78MR5xOl0rN5JGtk3HIMbP-06ubP6HXfgTw-o9c9KcPt7ucMj1vncb08ZM0OMK8RWzOBQLkrlOpGkbotpBeWY5nzPxIXgziKQtcDr97IOKED5zaqDLvTfRzZ-FoUvNDvxNqNeuJn075kIAQ-Pi3cn8QWsR18l2fFbOcU3S-HUPowbG05Xroyy8BZh3N6CvLEFsMAlNPCVGmZ3IUMPV5E402whdwzkZfPazzPX4YzwzV-7Nz7xr0n6Urfi_3ili2RgZIFCs3nwV618hgbWe7S73fWOU9IdPPJG7H8yaP35AhNxy2FjPvpfJm5kcSB7LXCLYACpq51M46rXWBmIMnXnWskMpNTqdWZyiafE2Dv-meU0G89ZXt_IcQ7k5zzTWr42ud0aROY8kIwOJqZ370uQYkGhKKwCTmn_G0KYH7DgFZvmA9KkKBJWJwvC8ex1sURRZsY1XHka4VrfITWkSZ8jRXAhIqfyjz2YBCcw7AJK6j6DqHpLmeCeeT6EOKnl7auSrmwVtuylBBn4br7qduQ==",
      "text": "OSE Immunotherapeutics Propose une Evolution de sa Gouvernance et R\u00e9affirme ses Priorit\u00e9s Strat\u00e9giques \u00e0 l\u2019Approche de son Assembl\u00e9e G\u00e9n\u00e9rale Annuelle\n25/08/2025\nActiver les cellules T cytotoxiques au travers de n\u00e9o-\u00e9pitopes Transformer les cellules suppressives du micro-environnement tumoral en cellules effectrices\nR\u00e9guler \u00e0 la baisse les cellules T effectrices pour diminuer la r\u00e9activit\u00e9 immunologique R\u00e9guler \u00e0 la hausse les cellules T r\u00e9gulatrices pour renforcer la tol\u00e9rance immunitaire\nTrois plateformes de recherche brevet\u00e9es dont l\u2019objectif est de d\u00e9livrer des traitements d\u2019immunoth\u00e9rapie first-in-class\nDes partenariats pharmaceutiques, cliniques et acad\u00e9miques internationaux pour d\u00e9velopper des innovations de rupture et r\u00e9pondre au plus vite aux patients en attente de nouvelles options th\u00e9rapeutiques\nVous confirmez que vous avez lu notre politique de confidentialit\u00e9. Vous pouvez vous inscrire ou vous d\u00e9sinscrire \u00e0 tout moment en utilisant le lien pr\u00e9vu \u00e0 cet effet."
    },
    {
      "url": "https://www.globenewswire.com/Tracker?data=Mhkt4Dxw5j5LSHTXwp6-ydYYsMnbrtKoDEeKIO5J8XN36qjVa0tBsIrLpAX_Hz3zJIGayNylUnOzICGK9HmwUcdCLn9zTYG1p9TrMua3LrZoavH4o_J8258pByv58QePeL_9UuUFv6dOY-X_HbAWQQ==",
      "text": "OSE Immunotherapeutics propose une \u00e9volution de sa gouvernance pour accompagner sa nouvelle trajectoire de croissance \ud83d\udfe6 Dans le paysage biotechnologique actuel, agilit\u00e9, clart\u00e9 et comp\u00e9titivit\u00e9 internationale sont essentielles. \u00c0 l\u2019approche de son Assembl\u00e9e G\u00e9n\u00e9rale, OSE Immunotherapeutics propose une \u00e9volution juste et tourn\u00e9e vers l\u2019avenir de sa structure de gouvernance. Cette proposition vise \u00e0 garantir une repr\u00e9sentation \u00e9quilibr\u00e9e des actionnaires et \u00e0 positionner la soci\u00e9t\u00e9 pour une croissance durable. \ud83e\udded OSE aujourd\u2019hui n\u2019est plus l\u2019OSE de 2015. Nous reconnaissons les contributions du pass\u00e9, mais regarder en arri\u00e8re freine notre progression. Notre responsabilit\u00e9 est de faire avancer OSE \u2014 avec plus de force, d\u2019ambition et en coh\u00e9rence avec les r\u00e9alit\u00e9s scientifiques, \u00e9conomiques et financi\u00e8res d\u2019aujourd\u2019hui. \ud83d\udcc8 Notre strat\u00e9gie est r\u00e9solument tourn\u00e9e vers l\u2019avenir : valoriser pleinement Tedopi\u00ae et Lusvertikimab, avec rigueur, clart\u00e9 et vision. \ud83e\udd1d La repr\u00e9sentation au sein du Conseil doit refl\u00e9ter l\u2019actionnariat et servir les int\u00e9r\u00eats de l\u2019ensemble des parties prenantes. Il est \u00e9galement essentiel de rappeler le r\u00f4le des administrateurs ind\u00e9pendants : ils sont mandat\u00e9s pour repr\u00e9senter tous les actionnaires \u2014 et non une minorit\u00e9. Ce principe est au c\u0153ur d\u2019une gouvernance saine et de d\u00e9cisions prises dans l\u2019int\u00e9r\u00eat de la soci\u00e9t\u00e9 et de sa base d\u2019investisseurs. \ud83d\udee1\ufe0fNous poursuivons un dialogue actif avec les actionnaires concertistes et esp\u00e9rons parvenir \u00e0 une compr\u00e9hension commune, dans l\u2019int\u00e9r\u00eat des patients, des actionnaires et de l\u2019avenir d\u2019OSE. C\u2019est un moment qui appelle \u00e0 un leadership r\u00e9fl\u00e9chi \u2014 avec int\u00e9grit\u00e9, respect et une vision claire de ce qui est \u00e0 venir. En lire plus : https://lnkd.in/e5g7UdWD #Gouvernance #Strat\u00e9gieBiotech #Innovation #AGM2025\nOSE Immunotherapeutics\nBiotechnology Research\nNANTES, PAYS DE LA LOIRE 19,260 followers\nImmuno-Oncology and Immuno-Inflammation - Breakthrough Immuno-Science for Patients\nAbout us\nOSE Immunotherapeutics, a biotech dedicated to developing first-in-class assets in immuno-oncology (IO) & immuno-inflammation (I&I). \u2022 Tedopi\u00ae (therapeutic cancer vaccine): Registration Phase 3 in 2nd-line NSCLC in HLA-A2+ patients with secondary resistance. Phase 2 trials, sponsored by onco groups, of Tedopi\u00ae in combo in solid tumors. \u2022 Lusvertikimab (mAb IL-7R antagonist); Positive Phase 2 in UC; preclinical research in ALL. \u2022 OSE-279 (anti-PD1): 1st positive results in Phase 1/2 in solid tumors. \u2022 FR-104/VEL-101 (anti-CD28 mAb): developed in partnership with Veloxis in transplant; Phase 1/2 in renal transplant (CHU Nantes); successful Phase 1 in the US (Veloxis). \u2022 Anti-SIRP\u03b1 mAb developed in partnership with Boehringer Ingelheim in advanced solid tumors & cardiovascular-renal-metabolic diseases; positive Phase 1 dose escalation results in monotherapy and combo; Phase 2 in CRM diseases planned end 2024. \u2022 ABBV-230 (ChemR23 agonist mAb) developed in partnership with AbbVie in chronic inflammation. 4 proprietary drug discovery platforms \u2022 Pro-resolutive mAb platform \u2022 Myeloid Checkpoint platform \u2022 BiCKI\u00ae Platform \u2022 mRNA Therapeutic platform f\n- Website\n-\nhttps://ose-immuno.com\nExternal link for OSE Immunotherapeutics\n- Industry\n- Biotechnology Research\n- Company size\n- 51-200 employees\n- Headquarters\n- NANTES, PAYS DE LA LOIRE\n- Type\n- Public Company\n- Founded\n- 2012\n- Specialties\n- Immuno-oncologie, Immunoth\u00e9rapie, Maladies autoimmunes, NSCLC, Checkpoint inhibitor, D\u00e9veloppement clinique, Biotechnologie, N\u00e9o-\u00e9pitopes, SIRP-alpha, MDSC, Rectocolite h\u00e9morragique, and Polyarthrite rhumato\u00efde\nLocations\n-\nPrimary\nGet directions\n22, avenue B\u00e9noni Goullin\nNANTES, PAYS DE LA LOIRE 44200, FR\n-\nGet directions\n100, avenue de Suffren\nPARIS, ILE DE FRANCE 75015, FR\nEmployees at OSE Immunotherapeutics\n-\nMarc Dechamps\nChief Executive Officer at Bioxodes\n-\nLaurie Cordonnier\nChief of Translational Research and Alliances\n-\nSophie Brouard\nDoctor at INSERM | Research in Immunoregulation And Immunointervention in Transplantation and Autoimmunity | Recipient in 2020 of CNRS Innovation\u2026\n-\nSilvia Comis, MD\nChief Clinical and Medical Research Officer - OSE Immunotherapeutics\nUpdates\n-\nOSE Immunotherapeutics Proposes Governance Evolution to Support Its Next Strategic Chapter \ud83d\udfe6 In today\u2019s biotech landscape, agility, clarity, and global competitiveness are essential. Ahead of our Annual General Meeting, OSE Immunotherapeutics is proposing a fair and forward-looking evolution of our Board structure. This change is designed to ensure balanced shareholder representation and to position the company for sustainable growth. \ud83e\udded OSE today is not the OSE of 2015. While we acknowledge the contributions of past stewards, looking backwards only hinders our growth. Our responsibility is to drive OSE forward; stronger and more ambitious and aligned with today\u2019s scientific, market, and funding realities. \ud83d\udcc8 Our strategy is therefore resolutely future-focused\u2014unlocking the full potential of Tedopi\u00ae and Lusvertikimab, guided by discipline, clarity, and a future-driven vision. \ud83e\udd1d Representation on the Board should reflect ownership and must drive what is best for the company and all of its stakeholders. And, it is also important to reaffirm the role of independent directors: they are entrusted to represent the interests of all shareholders\u2014not just a select few. This principle is central to good governance and to ensuring decisions are made in the best interest of the company and its broader investor base. \ud83d\udee1\ufe0fWe remain in active dialogue with concertist shareholders and hope to reach a shared understanding that serves the best interests of patients, shareholders, and the future of OSE. This is a moment for thoughtful leadership \u2014 with integrity, respect, and a clear vision for what comes next. Read more: https://lnkd.in/eGihk5ZP #Governance #BiotechStrategy #InnovationForward #AGM2025\n-\nJoin us in welcoming Thomas Gidoin to OSE Immunotherapeutics as the Chief Financial Officer and a member of the Executive Committee. He brings deep international expertise in capital markets, financial strategy and governance to the company as we enter a new phase of financial leadership. Read the press release to learn more: https://lnkd.in/ejKT9VEk #Biotechnology #ChiefFinancialOfficer #Innovation\n-\nRejoignez-nous pour souhaiter la bienvenue \u00e0 Thomas Gidoin au sein d\u2019OSE en tant que Directeur Financier et membre du Comit\u00e9 Ex\u00e9cutif ! Il apporte \u00e0 la Soci\u00e9t\u00e9 une large exp\u00e9rience internationale dans les march\u00e9s financiers, la strat\u00e9gie financi\u00e8re et la gouvernance, marquant une nouvelle \u00e9tape dans le pilotage financier. Lire le communiqu\u00e9 de presse : https://lnkd.in/eZFTNkPw #Biotechnologie#DirecteurFinancier#Innovation\n-\nWe congratulate our partner Veloxis on the preclinical efficacy results of pegrizeprument, which they will soon be presenting at a major international congress. We\u2019re looking forward to their presentation!\nWe\u2019re excited to present new preclinical data on pegrizeprument (also known as VEL-101) at #WTC2025! The abstract will be presented on Tuesday, August 5 by Daniel Schuster, MD, MS, General Surgery Resident at Duke University Medical Center. Pegrizeprument is a novel subcutaneous CD28 co-stimulation blocker being developed as maintenance immunosuppression in kidney transplantation. Read more here: https://lnkd.in/ezGZq5nY\n-\nWorld Lung Cancer Day Lung cancer affects millions of people a year. Non-small cell lung cancers (NSCLC) account for approximately 85% of that. This #WorldLungCancerDay, we\u2019re raising awareness for every single patient battling this devastating disease. At OSE Immunotherapeutics, we are dedicated to the research and development of immuno-oncology therapies that may eventually help patients with #NSCLC fight those battles. Today and every day, let\u2019s work together to find a treatment that can improve patient outcomes. #LungCancerAwareness #ImmunoOncology\n-\nJourn\u00e9e Mondiale du Cancer du poumon Le cancer du poumon touche des millions de personnes chaque ann\u00e9e. Le cancer du poumon non \u00e0 petites cellules (CPNPC) concerne environ 85 % d\u2019entre elles. La #Journ\u00e9eMondialeCancerduPoumon est l\u2019occasion de se mobiliser pour chaque patient qui lutte contre cette maladie d\u00e9vastatrice. Chez OSE Immunotherapeutics, nous sommes pleinement engag\u00e9s dans la recherche et le d\u00e9veloppement de traitements innovants d\u2019immuno-oncologie qui pourraient aider les patients atteints d\u2019un CPNPC \u00e0 mener leur combat. Aujourd\u2019hui et chaque jour, unissons nos efforts pour trouver un traitement qui puisse am\u00e9liorer le pronostic des patients ! #SensibilisationCancerPoumon#ImmunoOncologie\n-\nIl a \u00e9t\u00e9 port\u00e9 \u00e0 notre attention que le site Boursorama mentionne une publication des r\u00e9sultats semestriels d\u2019OSE Immunotherapeutics le 23 juillet. Nous confirmons que cette date ne correspond pas \u00e0 notre calendrier de communication financi\u00e8re. Pour consulter les dates indicatives de publication des r\u00e9sultats semestriels et de l\u2019Assembl\u00e9e G\u00e9n\u00e9rale, veuillez vous r\u00e9f\u00e9rer \u00e0 notre site internet. --//-- It has come to our attention that the Boursorama website mentions a publication of OSE Immunotherapeutics\u2019 half-year results on July 23. We confirm that this date does not correspond to our financial communication calendar. Please refer to our website for the indicative dates for our semestrial results and AGM.\n-\nOSE Immunotherapeutics Launches Newsletter for Individual Shareholders As OSE Immunotherapeutics marks the 10th anniversary of its listing on Euronext Paris, the company is proud to launch a new communication channel dedicated to its individual shareholders. \u201cThis milestone year is the perfect moment to strengthen our dialogue with those who have supported us along the way,\u201d said Fiona Olivier, Chief Corporate Affairs & Investor Relations Officer. \u201cThrough this newsletter, we aim to provide transparent, timely updates and share the scientific and strategic progress shaping OSE\u2019s future.\u201d Read more : https://lnkd.in/eYycQTk2\n-\nOSE Immunotherapeutics lance une Newsletter pour les investisseurs individuels \u00c0 l\u2019occasion du 10e anniversaire de son introduction en bourse sur Euronext Paris, OSE Immunotherapeutics est fi\u00e8re de lancer un nouveau canal de communication d\u00e9di\u00e9 \u00e0 ses actionnaires individuels. \u00ab Cette ann\u00e9e anniversaire est le moment id\u00e9al pour renforcer notre dialogue avec celles et ceux qui nous ont soutenus tout au long de notre parcours \u00bb, a d\u00e9clar\u00e9 Fiona Olivier, Directrice des Affaires Corporate et des Relations Investisseurs. \u00ab \u00c0 travers cette newsletter, nous souhaitons fournir des informations transparentes et actualis\u00e9es, et partager les avanc\u00e9es scientifiques et strat\u00e9giques qui fa\u00e7onnent l\u2019avenir d\u2019OSE. \u00bb En lire plus : https://lnkd.in/e52FBAdZ"
    }
  ],
  "argos_summary": "OSE Immunotherapeutics is proposing a new board structure that balances independent directors, concertist shareholders, the CEO, and employee representation to support its next strategic phase and maintain agile governance. The company remains focused on advancing its two flagship programs, Tedopi\u00ae (phase\u202f3 lung\u2011cancer study) and Lusvertikimab (cost\u2011efficient phase\u202f2b to refine dosing and biomarker strategy), while exploring partnership and financing options. The upcoming Annual General Meeting on September\u202f30, 2025 will feature electronic voting, a live broadcast, and a shareholder webinar on September\u202f18 to discuss these developments. OSE also highlighted its broader research portfolio and reaffirmed its commitment to unlocking the full potential of its immuno\u2011oncology and immuno\u2011inflammation assets.",
  "argos_id": "RU06CCZQJ"
}